ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 2107

Efficacy and Safety of Inebilizumab for the Treatment of IgG4-RD Across Age Subgroups: Analysis from the Open-label Period of the MITIGATE Trial

John Stone1, Emma Culver2, Arezou Khosroshahi3, Wen Zhang4, Emanuel Della-Torre5, Kazuichi Okazaki6, Yoshiya Tanaka7, Matthias Löhr8, Nicolas Schleinitz9, Lingli Dong10, Hisanori Umehara11, Marco Lanzillotta12, Mikael Ebbo13, Fernando Martínez-Valle14, Manu Nayar15, Vinciane Rebours16, Cory Perugino17, Sarah Bray18, Zachary Wallace19, Kelly Steed20, Maya Osman21, Sue Cheng20 and Daniel Cimbora20

Affiliations: 1Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Concord, MA, 2Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, oxford, England, United Kingdom, 3Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 4Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 5Università Vita-Salute San Raffaele, Milan, Italy; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UNIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy, 6Department of Internal Medicine, Kansai Medical University Kori Hospital, Osaka, Japan, 7Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden, 9Departement de Médecine Interne, Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France, 10Huazhong University of Science and Technology, Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Wuhan, China (People's Republic), 11Department of Rheumatology and Immunology, Nagahama City Hospital, Nagahama, Shiga 526-0043, Japan, Japan, 12IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, Milan, Italy, 13Departement de Medecine Interne Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France, 14Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain, 15Freeman Hospital, Hepato-Pancreato-Biliary Unit, Newcastle upon Tyne, United Kingdom, 16Université Paris-Cité, Pancreatology and Digestive Oncology Department, Beaujon Hospital, AP-HP, Clichy, Paris, France, 17Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 18Amgen Ltd., Cambridge, United Kingdom, 19Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, 20Amgen Inc., Thousand Oaks, CA, 21Amgen Inc., Dearborn, MI

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: clinical trial, IgG4 Related Disease

Session Information

Date: Tuesday, November 10, 2026

Title: (2096-2128) Vasculitis - Non-ANCA-Associated & Related Disorders - Clinical Poster C

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a chronic, systemic fibroinflammatory disease characterized by unpredictable and recurrent flares, leading to progressive organ damage and decreased quality of life. Inebilizumab (INEB) is a humanized, glycoengineered CD19-directed monoclonal antibody that selectively depletes B cells, including plasmablasts and some plasma cells implicated in IgG4-RD pathogenesis. INEB was found to be safe and effective in the MITIGATE trial (NCT04540497), an international, randomized, double-blind, placebo (PBO)-controlled phase 3 trial (Stone et al., 2025). We present a subgroup analysis of the MITIGATE open-label period (OLP) evaluating the efficacy and safety of INEB in participants aged < 65 years and ≥65 years.

Methods: Eligible participants who completed the randomized controlled period (RCP) of the MITIGATE trial could enroll in an optional 3-year OLP. During the OLP, all enrolled participants received INEB 300 mg intravenously every 6 months after having received PBO (PBO/INEB group) or INEB (INEB/INEB group) in the preceding RCP. This post hoc subgroup analysis evaluated participant incidence of treated and adjudication committee (AC)-determined IgG4-RD flares, annualized flare rate, proportion of participants with glucocorticoid (GC) use for disease control, mean total GC use, and long-term safety in participants aged < 65 years and ≥65 years using data available at the time the last participant completed 1 year in the OLP.

Results: Of the 127 participants who completed RCP, 107 (84.3%) entered the OLP. Baseline characteristics were well balanced across the two treatment groups for both age subgroups. The median disease duration was 0.90 years (min 0.1, max 20.5) among < 65 years participants, and 0.65 years (min 0.1, max 8.5) among ≥65 years participants. During the first year of OLP, no participants in the INEB/INEB group experienced an IgG4-RD. In the PBO/INEB group, 3/38 (7.9%) participants (all < 65 years) experienced a flare during the OLP. The annualized flare rate was low in both age subgroups (Table 1). GC use remained low in the INEB/INEB group, with only 1/41 (2.4%) participants aged < 65 years requiring GCs, and no GC use was reported among any participants aged ≥65 years. No GC use (mean total dose) was observed among participants aged ≥65 years in the INEB/INEB group; mean total GC dose was 5.98 mg in those aged < 65 years (Table 1). TEAEs were generally comparable across age groups (< 65 vs ≥65 years), with numerically higher rates of nasopharyngitis, urinary tract infection, pyrexia, back pain, and lymphopenia among patients aged ≥65 years.

Conclusion: In the OLP of the MITIGATE trial, similar clinical benefit was observed across age-stratified subgroups (< 65 vs ≥65 years). INEB was associated with a reduced incidence of flares and lower GC use, demonstrating sustained clinical benefit. No new safety signals were identified in these subgroups relative to the RCP (Stone et al., NEJM 2024). These results suggest INEB may serve as a longer-term treatment option for IgG4-RD in both young and elderly participants.

Supporting image 1


Disclosures: J. Stone: AcepodiaBio, 12,, Amgen, 12,, Bristol-Myers Squib, 12,, HingeBio, 12,, Merck, 12,, National Institutes of Health (UM1 AI144295 - Autoimmunity Center of Excellence), 12,, Novartis, 12,, Q32Bio, 12,, Sanofi, 12,, Steritas, 12,, Zenas, 12,, ZipBio, 12,; E. Culver: Amgen, 12,; A. Khosroshahi: Acepodia, 12,, Amgen Inc., 12,, Sanofi, 12,, Zenas BioPharma, 12,; W. Zhang: Amgen Inc., 12,; E. Della-Torre: Acepodia, 12,, Amgen Inc., 12,, Bristol-Myers Squibb(BMS), 12,, Hoffmann-La Roche, 12,, Recordati Rare Diseases, 12,, Sanofi, 12,, Zenas BioPharma, 12,; K. Okazaki: Amgen Inc., 12,; Y. Tanaka: AbbVie, 12,, AstraZeneca, 12,, Boehringer Ingelheim, 12,, Bristol Myers Squibb, 12,, Chugai, 12,, Daiichi-Sankyo, 12,, Eisai, 12,, Eli Lilly and Company, 12,, Gilead, 12,, GSK, 12,, IQVIA, 12,, Novartis, 12,, Otsuka, 12,, Taisho, 12,, UCB, 12,; M. Löhr: Amgen Inc., 12,; N. Schleinitz: Amgen Inc., 12,; L. Dong: Amgen Inc., 12,; H. Umehara: Amgen Inc., 12,; M. Lanzillotta: Amgen Inc., 12,; M. Ebbo: Amgen Inc., 12,; F. Martínez-Valle: Amgen Inc., 12,, Medpace, 12,, Novartis, 12,; M. Nayar: Amgen Inc., 12,; V. Rebours: Amgen Inc., 12,; C. Perugino: Amgen Inc., 12,, Spero Therapeutics, 12,, Zenas Biopharma, 12,; S. Bray: Amgen Ltd., 12,, 12, ; Z. Wallace: Amgen Inc., 12,, 12, , 12, ; K. Steed: Amgen, 12,, 12, ; M. Osman: Amgen Inc., 12,, 12, ; S. Cheng: Amgen Inc., 12,, 12, ; D. Cimbora: Amgen Inc., 12,, 12, .

To cite this abstract in AMA style:

Stone J, Culver E, Khosroshahi A, Zhang W, Della-Torre E, Okazaki K, Tanaka Y, Löhr M, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Ebbo M, Martínez-Valle F, Nayar M, Rebours V, Perugino C, Bray S, Wallace Z, Steed K, Osman M, Cheng S, Cimbora D. Efficacy and Safety of Inebilizumab for the Treatment of IgG4-RD Across Age Subgroups: Analysis from the Open-label Period of the MITIGATE Trial [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-inebilizumab-for-the-treatment-of-igg4-rd-across-age-subgroups-analysis-from-the-open-label-period-of-the-mitigate-trial/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-inebilizumab-for-the-treatment-of-igg4-rd-across-age-subgroups-analysis-from-the-open-label-period-of-the-mitigate-trial/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology